CD274 and non-small cell lung carcinoma: Programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors have been approved as standard treatments for non-small cell lung cancer (NSCLC) without targeted mutations based on studies showing improved survival over chemotherapy (2–7).